 
        
        
        
                货号:A767723
                
                同义名:
                    
                        
                            
                                Casein kinase II Inhibitor; CK2 Inhibitor
                            
                        
                    
                
                
                
                    
                     
                    
                     
                
            
DMAT是一种特异性的酪蛋白激酶 (CK2) 抑制剂,IC50约为130 nM,用于研究各种酪蛋白激酶相关病理过程。
 
                                 
                                
                            

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + | 
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
 
                        
                    
| 产品名称 | CK1 ↓ ↑ | CK2 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PF-670462 2HCl | ++++ CK1ε, IC50: 90 nM CK1δ, IC50: 13 nM | 99%+ | |||||||||||||||||
| D4476 | ++ CK1 from Schizosaccharomyces pombe, IC50: 200 nM CK1δ, IC50: 300 nM | 99% | |||||||||||||||||
| SR-3029 | +++ CK1ε, IC50: 260 nM CK1δ, IC50: 44 nM | 99%+ | |||||||||||||||||
| IWP-2 | +++ M82FCK1δ, IC50: 40 nM | Wnt | 99% | ||||||||||||||||
| LY364947 | ++ CK1δ, IC50: 0.22 μM | 98% | |||||||||||||||||
| TA-01 | ++++ CK1ε, IC50: 6.4 nM CK1δ, IC50: 6.8 nM | p38 MAPK | 99%+ | ||||||||||||||||
| IC261 | + CK1, IC50: 16 μM | 98% | |||||||||||||||||
| PF-4800567 | +++ casein kinase 1 delta, IC50: 711 nM casein kinase 1 epsilon, IC50: 32 nM | 99%+ | |||||||||||||||||
| CK1-IN-1 | ++++ CK1ε, IC50: 16 nM CK1δ, IC50: 15 nM | 99% | |||||||||||||||||
| Longdaysin | + CKIδ, IC50: 8.8 μM CKIα, IC50: 5.6 μM | 99%+ | |||||||||||||||||
| Silmitasertib | ++++ CK2, IC50: 1 nM | 99%+ | |||||||||||||||||
| Ellagic acid (hydrate) | +++ CK2, IC50: 0.04 μM | PKA | 95+% | ||||||||||||||||
| DMAT | +++ CK2, Ki: ~40 nM | 99% | |||||||||||||||||
| Hematein | ++ CK2, IC50: 0.55 μM | 40% | |||||||||||||||||
| Silmitasertib sodium salt | ++++ CK2α', IC50: 1 nM CK2α, IC50: 1 nM | 99%+ | |||||||||||||||||
| LY294002 | +++ CK2, IC50: 98 nM | 99%+ | |||||||||||||||||
| A-3 HCl | + CK1, Ki: 80 μM | ++ CK2, Ki: 5.1 μM | PKC,MLCK,PKA | 98+% | |||||||||||||||
| TBB | + CK1, Ki: 47 μM | ++ CK2, Ki: 0.4 μM | 98% | ||||||||||||||||
| TTP 22 | ++ CK2, IC50: 100 nM | 98%+ | |||||||||||||||||
| DRB | ✔ | 99%+ | |||||||||||||||||
| BioE-1115 | + CK2α, IC50: 10 μM | 99%+ | |||||||||||||||||
| (E/Z)-GO289 | ++++ CK2, IC50: 7 nM | 99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 | 
 | 
| 描述 | DMAT is a potent and specific CK2 inhibitor with an IC50 value of 130 nM. | 
| Concentration | Treated Time | Description | References | |
| GBC | 10 µM | 72 hours | DMAT significantly reduces cell viability and induces apoptosis | Int J Biol Sci. 2012;8(1):15-29. | 
| SkChA-1 | 10 µM | 72 hours | DMAT significantly reduces cell viability and induces apoptosis | Int J Biol Sci. 2012;8(1):15-29. | 
| MzChA-2 | 10 µM | 72 hours | DMAT significantly reduces cell viability and induces apoptosis | Int J Biol Sci. 2012;8(1):15-29. | 
| MzChA-1 | 10 µM | 72 hours | DMAT significantly reduces cell viability and induces apoptosis | Int J Biol Sci. 2012;8(1):15-29. | 
| CCSW-1 | 10 µM | 72 hours | DMAT significantly reduces cell viability and induces apoptosis | Int J Biol Sci. 2012;8(1):15-29. | 
| Human brain microvascular endothelial cells (HBMVEC) | 50-100 μM | 8 hours | DMAT induced dramatic changes in cell shape, including cell retraction and rounding, which were reversible within 8 hours. | Mol Cell Biochem. 2011 Mar;349(1-2):125-37. | 
| Human astrocytes (HAST-40) | 50-100 μM | 6 hours | DMAT induced dramatic changes in cell shape, including cell retraction and rounding, which were reversible within 6 hours. | Mol Cell Biochem. 2011 Mar;349(1-2):125-37. | 
| TFK | 10 µM | 72 hours | DMAT significantly reduces cell viability and induces apoptosis | Int J Biol Sci. 2012;8(1):15-29. | 
| EGI-1 | 10 µM | 72 hours | DMAT significantly reduces cell viability and induces apoptosis | Int J Biol Sci. 2012;8(1):15-29. | 
| 3T3-L1 cells | 30 µM | Inhibited adipogenesis in 3T3-L1 cells | Molecules. 2021 Aug 5;26(16):4747. | |
| BDC | 10 µM | 72 hours | DMAT significantly reduces cell viability and induces apoptosis | Int J Biol Sci. 2012;8(1):15-29. | 
| CCLP-1 | 10 µM | 72 hours | DMAT significantly reduces cell viability, induces apoptosis, and inhibits Wnt signaling pathway | Int J Biol Sci. 2012;8(1):15-29. | 
| UM-SCC-46 | 10, 20 μM | 48 hours | Inhibited mRNA expression of CSC marker genes Nanog, Oct4, and Sox2 | Neoplasia. 2014 Oct 23;16(10):789-800. | 
| UM-SCC-22A | 10, 20 μM | 48 hours | Inhibited mRNA expression of CSC marker genes Nanog, Oct4, and Sox2 | Neoplasia. 2014 Oct 23;16(10):789-800. | 
| H1299 cells | 2.5 or 12.5 µM | 20 hours | Inhibition of CK2 activity, reduction of E1B-55K phosphorylation | J Virol. 2012 Mar;86(5):2400-15. | 
| A549 cells | 2.5 or 12.5 µM | 20 hours | Inhibition of CK2 activity, reduction of E1B-55K phosphorylation | J Virol. 2012 Mar;86(5):2400-15. | 
| HMDM cells | 1μM | 15h | DMAT significantly stimulated HMDM cells to kill VRE bacteria | ACS Infect Dis. 2024 May 10;10(5):1725-1738. | 
| RAW264.7 cells | 1μM | 15h | DMAT significantly stimulated RAW264.7 cells to kill VRE bacteria | ACS Infect Dis. 2024 May 10;10(5):1725-1738. | 
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Wound infection model | IP injection | 5mg/kg | Single dose | DMAT significantly reduced VRE bacterial load in wounds | ACS Infect Dis. 2024 May 10;10(5):1725-1738. | 
| 计算器 | ||||
| 存储液制备 |  | 1mg | 5mg | 10mg | 
| 1 mM 5 mM 10 mM | 2.10mL 0.42mL 0.21mL | 10.49mL 2.10mL 1.05mL | 20.97mL 4.19mL 2.10mL | |
| CAS号 | 749234-11-5 | 
| 分子式 | C9H7Br4N3 | 
| 分子量 | 476.79 | 
| SMILES Code | CN(C)C1=NC2=C(Br)C(Br)=C(Br)C(Br)=C2N1 | 
| MDL No. | MFCD08705322 | 
| 别名 | Casein kinase II Inhibitor; CK2 Inhibitor; 2-Dimethylamino-4,5,6,7-tetrabromobenzimidazole; Casein Kinase II Inhibitor II | 
| 运输 | 蓝冰 | 
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, store in freezer, under -20°C | 
| 溶解方案 | DMSO: 50 mg/mL(104.87 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 
 | 
 沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1
			沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1